Tamoxifen
- Generic Name
- Tamoxifen
- Brand Names
- Soltamox
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29NO
- CAS Number
- 10540-29-1
- Unique Ingredient Identifier
- 094ZI81Y45
- Background
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with anastrozole.
Tamoxifen was granted FDA approval on 30 December 1977.
- Indication
Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.
- Associated Conditions
- Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
- Associated Therapies
- Ovulation induction therapy
Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-10-22
- Last Posted Date
- 2015-05-18
- Lead Sponsor
- Medical College and Hospital Kolkata
- Target Recruit Count
- 256
- Registration Number
- NCT00999921
- Locations
- 🇮🇳
Department of Surgery, Medical College, Kolkata, Kolkata, West Bengal, India
CYP2D6 Genotype on the Clinical Effect of Tamoxifen
- Conditions
- Interventions
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2009-09-09
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 922
- Registration Number
- NCT00973037
- Locations
- 🇰🇷
Korea University Anam Hopital, Seoul, Korea, Republic of
Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant
- Conditions
- First Posted Date
- 2009-06-12
- Last Posted Date
- 2009-06-12
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 15
- Registration Number
- NCT00919399
- Locations
- 🇫🇷
CHU de Toulouse Rangueil, Toulouse, France
🇫🇷Institut Claudius Regaud, Toulouse, France
Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2009-06-16
- Lead Sponsor
- Korean Breast Cancer Study Group
- Target Recruit Count
- 1234
- Registration Number
- NCT00912548
- Locations
- 🇰🇷
Department of Surgery, Korea Cancer Center Hospital, Seoul, Korea, Republic of
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2017-08-25
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 121
- Registration Number
- NCT00900744
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients
- First Posted Date
- 2009-05-11
- Last Posted Date
- 2011-08-30
- Lead Sponsor
- Tata Memorial Hospital
- Target Recruit Count
- 260
- Registration Number
- NCT00896155
- Locations
- 🇮🇳
Tata Memorial Center, Parel, Mumbai, India
Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2018-03-15
- Lead Sponsor
- AEterna Zentaris
- Target Recruit Count
- 10
- Registration Number
- NCT00847366
Zoladex Plus Tamoxifen in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2011-08-08
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT00827307
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
ATAC - Pharmacokinetics (PK) Sub-Protocol
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2009-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 9358
- Registration Number
- NCT00784862
ATAC - Quality of Life Sub-Protocol
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2009-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 308
- Registration Number
- NCT00784680
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.